Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2018-05-07 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于2018年累计新增借款超过上年末净资产百分之二十的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by 瑞康医药股份有限公司 regarding the cumulative new borrowings in 2018 exceeding 20% of the previous year's net assets. It includes specific financial data about borrowings and their impact on debt repayment ability. The document references regulatory requirements for disclosure related to bond issuance and trading rules. The content is focused on a capital/financing update, specifically about new borrowings and their proportions relative to net assets. The document length is short (1192 characters), and it is not a full financial report but an announcement of financing activity. Therefore, it fits best under the category Capital/Financing Update (CAP).
2018-05-07 Chinese
国金证券股份有限公司关于公司2017年面向合格投资者公开发行公司债券（第一期）、2018年面向合格投资者公开发行公司债券（第一期）受托管理事务临时报告
Capital/Financing Update Classification · 95% confidence The document is a temporary report issued by the bond trustee (Guojin Securities) regarding the bond issuance and the borrowings of Ruikang Pharmaceutical Co., Ltd. It includes financial data such as net assets and borrowings, and highlights that the cumulative new borrowings exceed 40% of net assets, which is a significant event for bondholders. The document references audit reports and financial statements but does not itself contain a full annual report or audit report. It is a specific report related to bond trustee management and compliance with bond issuance regulations, focusing on debt and financing activities. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short (1688 characters) and contains substantive financial data related to financing, not just an announcement or certification, so it is not RPA or RNS.
2018-05-07 Chinese
关于为控股子公司提供担保及控股子公司之间互相提供担保的补充公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding guarantees provided by the company for its controlling subsidiaries and mutual guarantees among subsidiaries. It includes specifics about guarantee amounts, the purpose of guarantees, financial data of the guaranteed subsidiaries, board opinions, and independent directors' opinions. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is also not related to changes in management, voting results, or legal proceedings. The content focuses on capital and financing activities related to guarantees and credit facilities. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about financing guarantees, supporting this classification with high confidence.
2018-05-02 Chinese
关于公司董事、监事和高管计划通过有限合伙企业增持公司股份的进展公告
Director's Dealing Classification · 95% confidence The document is an announcement from a company about the progress of its directors, supervisors, and senior management increasing their shareholdings through a limited partnership. It details the number of shares held before and after the increase, the transaction method (secondary market bidding), and compliance with relevant laws and regulations. There is no financial report, earnings data, or management discussion of financial results. The document focuses on insider share transactions by company executives. Therefore, it fits the category of Director's Dealing (DIRS). The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2018-04-26 Chinese
独立董事对续聘会计师事务所的事前认可
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors regarding their prior approval for the reappointment of an accounting firm for the 2018 audit. It references regulatory guidance from the China Securities Regulatory Commission and company bylaws. The content is a formal attestation or certification about the auditor's reappointment rather than the audit report itself or detailed financial data. The document length is short (671 characters), and it does not contain financial statements or audit results. Therefore, it fits the category of a Regulatory Filing (RNS) as it is a formal regulatory announcement or certification related to audit matters but not the audit report itself.
2018-04-25 Chinese
2017年年度报告摘要
Annual Report Classification · 95% confidence The document is titled "瑞康医药股份有限公司 2017 年年度报告摘要" which translates to "Ruikang Pharmaceutical Co., Ltd. 2017 Annual Report Summary." It contains detailed financial data for the year 2017, including revenue, net profit, quarterly financial data, shareholder information, business overview, and strategic discussion. The document is comprehensive and covers the company's full financial performance and business activities for the fiscal year 2017. It is not a brief announcement or a presentation but a detailed summary of the annual report. Therefore, it fits the definition of an Annual Report (10-K). FY 2017
2018-04-25 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.